Ergotamine Targets KIF5A to Facilitate Anoikis in Lung Adenocarcinoma
The Clinical Respiratory Journal · 2024
DOI: 10.1111/crj.70020 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Clinical Respiratory Journal, 2024. Verfasst von Bin Bao und 3 weiteren Autor:innen. Beteiligte Einrichtung: Cardiothoracic Surgery Department, The First People's Hospital of Fuyang, Hangzhou, China. Hauptthemen laut MEDLINE: Adenocarcinoma of Lung, Kinesins, Anoikis, Lung Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical and Health Science and Technology Program of Zhejiang Province.
Abstract (Originalsprache)
Background
Kinesin family member 5A (KIF5A) has been reported to be closely related to cancer progression. The aim of this study was to investigate the effect of KIF5A on lung adenocarcinoma (LUAD) and its potential molecular mechanisms.
Methods
Using bioinformatics analysis methods and molecular experiments, the expression of KIF5A in LUAD was analyzed, with its expression in attached and detached tumor cells assessed. Gene set enrichment analysis (GSEA) of KIF5A was carried out. The small molecular drug with the highest affinity for KIF5A was screened out through molecular docking experiments, which was validated through cellular thermal shift assay (CETSA). Quantitative polymerase chain reaction (qPCR) was employed to measure the expression levels of anoikis‐repressing genes (BCL2, CAV1), as well as anoikis‐inducing gene (PDCD4). CCK‐8 assay was applied to examine cell viability. Cell colony formation experiments were utilized to evaluate cell proliferation ability.
Results
We observed that KIF5A was highly upregulated in LUAD tissues and cells, with a higher level detected in detached LUAD cells. By resorting to bioinformatics analysis, we discovered that KIF5A was abundant in the anoikis pathway. Knocking down KIF5A reinforced anoikis in LUAD. Further screening identified Ergotamine as the small molecular drug with the highest affinity for KIF5A. The CETSA confirmed the binding relationship between the two. In addition, Ergotamine has a promoting effect on the anoikis of LUAD, while overexpression of KIF5A reversed the effects of Ergotamine on LUAD cells.
Conclusion
This project uncovered that the small molecular drug Ergotamine targets and inhibits the expression of KIF5A. Downregulated KIF5A can enhance the anoikis of LUAD. Our results supported the inhibition of KIF5A as an attractive therapeutic strategy for LUAD. This finding provides a new innovative pathway for the treatment of LUAD and offers a strong theoretical basis for the development of therapeutic drugs targeting KIF5A.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cardiothoracic Surgery Department, The First People's Hospital of Fuyang, Hangzhou, China.
ORCID-Profile: Bin Bao
Förderung
- Medical and Health Science and Technology Program of Zhejiang Province
Zitieren
APA
Bao, B., Yu, X., Zheng, W., & Sun, J. (2024). Ergotamine Targets KIF5A to Facilitate Anoikis in Lung Adenocarcinoma. The Clinical Respiratory Journal. https://doi.org/10.1111/crj.70020
Vancouver
Bao B, Yu X, Zheng W, Sun J. Ergotamine Targets KIF5A to Facilitate Anoikis in Lung Adenocarcinoma. The Clinical Respiratory Journal. 2024. doi:10.1111/crj.70020
BibTeX
@article{Bao2024,
author = {Bao, Bin and Yu, Xiaojun and Zheng, Wujun and Sun, Jiewei},
title = {Ergotamine Targets KIF5A to Facilitate Anoikis in Lung Adenocarcinoma},
journal = {The Clinical Respiratory Journal},
year = {2024},
doi = {10.1111/crj.70020}
}
EUVIMED